Biotech News
Related news
ZURAZura Bio2026-08-31 20:30 EST
Zura Bio to Participate in the Cantor Global Healthcare Conference
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NRIXNurix Therapeutics2026-08-20 11:00 EST
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
CUECue Biopharma Inc2026-08-03 12:30 EST
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
BNTXBioNTech2026-08-03 09:00 EST
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
STTKShattuck Labs2026-10-01 11:00 EST
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
TLSATiziana Life Sciences2026-08-06 11:00 EST
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
ARGXArgenx2026-09-17 20:03 EST
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
INMBINmune Bio2026-10-06 13:00 EST
INmune Bio to Attend the 2026 Maxim Growth Summit
CABACabaletta Bio2026-10-05 20:01 EST
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zura Bio
Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...
Recent company news
ZURAZura Bio2026-08-31 20:30 EST
Zura Bio to Participate in the Cantor Global Healthcare Conference
ZURAZura Bio2026-08-21 23:57 EST
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ZURAZura Bio2026-08-11 11:30 EST
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
ZURAZura Bio2026-06-29 11:30 EST
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
ZURAZura Bio2026-05-14 11:30 EST
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 3.96 USD
- Market cap
- 389.01M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States